Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA.

J Clin Oncol. 2011 Aug 1;29(22):3085-96. doi: 10.1200/JCO.2010.33.2312. Epub 2011 Mar 7.

2.

Mutant BRAF melanomas--dependence and resistance.

Poulikakos PI, Rosen N.

Cancer Cell. 2011 Jan 18;19(1):11-5. doi: 10.1016/j.ccr.2011.01.008. Review.

3.

Epigenetics in alternative pre-mRNA splicing.

Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T.

Cell. 2011 Jan 7;144(1):16-26. doi: 10.1016/j.cell.2010.11.056. Review.

4.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M.

Cancer Cell. 2010 Dec 14;18(6):683-95. doi: 10.1016/j.ccr.2010.11.023.

5.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.

6.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.

Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.

7.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K.

Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.

8.

Inhibition of mutated, activated BRAF in metastatic melanoma.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.

N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.

9.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

10.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB.

Cancer Res. 2010 Jul 15;70(14):5901-11. doi: 10.1158/0008-5472.CAN-10-0192. Epub 2010 Jun 22.

11.

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R.

Sci Transl Med. 2010 Jun 9;2(35):35ra41. doi: 10.1126/scitranslmed.3000758.

12.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.

Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.

13.

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.

Cell. 2010 Jan 22;140(2):209-21. doi: 10.1016/j.cell.2009.12.040.

14.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
15.

A dimerization-dependent mechanism drives RAF catalytic activation.

Rajakulendran T, Sahmi M, Lefran├žois M, Sicheri F, Therrien M.

Nature. 2009 Sep 24;461(7263):542-5. doi: 10.1038/nature08314. Epub 2009 Sep 2.

PMID:
19727074
16.

Regulation and role of Raf-1/B-Raf heterodimerization.

Rushworth LK, Hindley AD, O'Neill E, Kolch W.

Mol Cell Biol. 2006 Mar;26(6):2262-72.

17.

BRAF mutation predicts sensitivity to MEK inhibition.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N.

Nature. 2006 Jan 19;439(7074):358-62. Epub 2005 Nov 6.

18.

The RAF proteins take centre stage.

Wellbrock C, Karasarides M, Marais R.

Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85. Review.

PMID:
15520807
19.

Active Ras induces heterodimerization of cRaf and BRaf.

Weber CK, Slupsky JR, Kalmes HA, Rapp UR.

Cancer Res. 2001 May 1;61(9):3595-8.

20.

Autoregulation of the Raf-1 serine/threonine kinase.

Cutler RE Jr, Stephens RM, Saracino MR, Morrison DK.

Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9214-9.

Supplemental Content

Support Center